2001-2002 Site Co-Investigator, Eli Lilly and Phase IIb Study to “A Determine the Efficacy and Safety of LY315920 in Patients with Severe Sepsis,” 2001-2003 Site Principal Investigator, Discovery Laboratories, Inc. “A Multicenter, Randomized, Controlled Trial Comparing The Safety and Effectiveness of SurfaxinÒ (Lucinactant) Delivered VIA Bronchopulmonary Segmental Lavage to Standard of Care in Patients With Acute Respiratory Distress Syndrome (ARDS).” 2002-2003 Co-Investigator, Clinical on Acute Core, “Specialized Lung Division of Pulmonary Injury” (RFA 96-HL-014), and Critical Care Medicine, $57,441. 2003-2004 Site Principal Investigator, Wyeth, Double-blind, “A Placebo-controlled, Randomized Study of the Efficacy and Safety of Etanercept in Patients with Idiopathic Pulmonary Fibrosis, $80,548. 2003-2004 Site Principal Investigator, IntraBiotics, Phase II/III “A Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Iseganan HCL Oral Solution in Preventing Ventilator-associated Pneumonia when Administered Orally to Intubated Patients Receiving Mechanical Endotracheal Ventilation, $296,470. 2002-2005 Lead Faculty for Pulmonary and Critical Care, to Strengthen Physicians' “Comprehensive Programs Geriatrics Training," D.W. Reynolds Foundation, $75,000. 2002-2005 Co-Investigator, NIH NHLBI ARDS Clinical Trials Rescue Study: The Efficacy of Network. “Late Steroid Corticosteroids as Rescue for the Late Phase of Acute Respiratory Distress and Syndrome,” “Prospective, Randomized, Multi-Center trial of ‘Fluid Conservative vs. of Acute Respiratory ‘Fluid Liberal’ Management Distress.” Total contract amount $2,708,312. 2005-2006 Site Principal Investigator, Pfizer, in the “Linezolid Treatment of Subjects with Nosocomial Pneumonia Proven to be Due to Staphlococcus aureus.”
2001-2002 Site Co-Investigator, Eli Lilly and “A Phase IIb Study to Determine the Efficacy and Safety of LY315920 in Patients with Severe Sepsis,” 2001-2003 Site Principal Investigator, Discovery Laboratories, Inc. “A Multicenter, Randomized, Controlled Trial Comparing The Safety and Effectiveness of SurfaxinÒ (Lucinactant) Delivered VIA Bronchopulmonary Segmental Lavage to Standard of Care in Patients With Acute Respiratory Distress Syndrome (ARDS).” 2002-2003 Co-Investigator, Clinical Core, “Specialized on Acute Lung Injury” (RFA 96-HL-014), Division of Pulmonary and Critical Care Medicine, $57,441. 2003-2004 Site Principal Investigator, Wyeth, “A Double-blind, Placebo-controlled, Randomized Study of the Efficacy and Safety of Etanercept in Patients with Idiopathic Pulmonary Fibrosis, $80,548. 2003-2004 Site Principal Investigator, IntraBiotics, “A Phase II/III Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Iseganan HCL Oral Solution in Preventing Ventilator-associated Pneumonia when Administered Orally to Intubated Patients Receiving Mechanical Endotracheal Ventilation, $296,470. 2002-2005 Lead Faculty for Pulmonary and Critical Care, “Comprehensive Programs to Strengthen Physicians' Geriatrics Training," D.W. Reynolds Foundation, $75,000. 2002-2005 Co-Investigator, NIH NHLBI ARDS Clinical Trials Network. “Late Steroid Rescue Study: The Efficacy of Corticosteroids as Rescue for the Late Phase of Acute Respiratory Distress Syndrome,” and “Prospective, Randomized, Multi-Center trial of ‘Fluid Conservative vs. ‘Fluid Liberal’ Management of Acute Respiratory Distress.” Total contract amount $2,708,312. 2005-2006 Site Principal Investigator, Pfizer, “Linezolid in the Treatment of Subjects with Nosocomial Pneumonia Proven to be Due to Staphlococcus aureus.”
Hyzy%20-%20CV%20-%202.4-2013%20-%20Final.docx